Students at Pittsburgh Dilworth PreK-5 found with heroin stamp bags
The bags are stamped with the words 'Take Off' and were found in the possession of several Pittsburgh Dilworth PreK-5 students.
PPS said Pittsburgh Police are trying to find out where the heroin came from and how students ended up with it.
Pittsburgh Dilworth families are asked to check their children's belongings and to contact 911 if they find the illegal substance in their items.
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) awarded the 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers who displayed exceptional innovation. The winners for 2025 are Dr. Alissandra L. Hillis, a postdoctoral fellow at MIT, and Mr. Sreekar Mantena, a Harvard-MIT M.D.-Ph.D. candidate and Broad Institute nominee. Each received an institutional award of $5,000 and $50,000. Copyright: delcreations / 123RF Stock Photo Top U.S. research institutions nominate candidates for the Regeneron Prize to submit 'dream projects' in biomedicine. Dr. Hillis from Professor Matthew Vander Heiden's lab suggested new methods for researching endometriosis. Mr. Mantena, who works under Professor Soumya Raychaudhuri at Brigham and Women's Hospital, wants to investigate thymic decrease with age using single-cell genomics. Seven other finalists earned $5,000 each. The prize has given out close to $2 million since it was established in 2013. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s broader STEM programs have reached 3.25 million students worldwide since 2020. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Yahoo
13 minutes ago
- Yahoo
Diddy doubles down on defamation lawsuit over alleged sex assault videos, seeks $100M
Sean "Diddy" Combs is escalating his legal battle against one of his accusers and the news outlet that helped publicize his claims. Combs, who sued Courtney Burgess in January for $50 million on allegations of defamation, amended his complaint against the man in the U.S. District Court for the Southern District of New York on Aug. 11, according to court documents obtained by USA TODAY. Burgess' attorney, Ariel Mitchell, and news broadcaster NewsNation are also named as defendants in the lawsuit. The Grammy-winning rapper is now seeking additional compensation, no less than $100 million in damages, for the harm caused by Burgess' "outlandish claims," which Combs' attorneys allege culminated in a "media frenzy" against the embattled hip-hop mogul. "People who heard and believed defendants' lies have accused Mr. Combs, on social media that is consumed by hundreds of millions of viewers each and every day, of being a debauched 'monster' and a pedophile," the lawsuit states. "The unrelenting tide of negative publicity and threatening social media posts resulting from defendants' lies have caused and will continue to cause Mr. Combs severe reputational harm." USA TODAY has reached out to Mitchell for comment. In an October 2024 interview aired by NewsNation, Burgess and Mitchell alleged that the man, who reportedly at one point testified in front of a grand jury for Combs' federal criminal case, possessed several videos purportedly showing Combs sexually assaulting minors, including celebrities, at his "freak off" sex parties. At the time of his original lawsuit in January, Combs, who was awaiting trial in his landmark sex crimes case, sought $50 million in damages for Burgess and Mitchell's claims. The disgraced music mogul said the pair's remarks about "freak off" footage had the potential to "poison the minds" of people who might serve on Combs' jury. Diddy takes legal action: Rap mogul files $50M defamation lawsuit over alleged sex assault videos Combs was arrested in September 2024 on charges of sex trafficking, racketeering and transportation to engage in prostitution. In July, the rapper was found guilty on two charges of transportation to engage in prostitution and acquitted of the remaining offenses. The rapper, who remains in custody at the Metropolitan Detention Center in Brooklyn, was denied bail on Aug. 4 after his legal team requested he be released on a $50 million bond. Contributing: KiMi Robinson, USA TODAY This article originally appeared on USA TODAY: Sean 'Diddy' Combs amends defamation lawsuit, now seeks $100 million
Yahoo
13 minutes ago
- Yahoo
Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735
Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year manufacturing contract to facilitate the commercial production of VK2735, the company's dual GLP-1/GIP agonist for obesity. The deal guarantees a yearly supply of more than 1 billion oral pills, 100 million autoinjectors, 100 million vial/syringe units, and several metric tons of API. Prepayments of $150 million will be made by the firm through 2028 and applied to upcoming orders. The agreement offers specific capacity for both oral and subcutaneous formulations. michaelheim/ Viking Therapeutics, Inc. (NASDAQ:VKTX)'s main metabolic therapy candidate, VK2735, is being developed as an injectable and oral medication. Phase 3 development for the injectable version is scheduled to start in Q2 2025, while the company is now completing a Phase 2 VENTURE-Oral trial. The business still owns global rights to VK2735. CEO Brian Lian noted that CordenPharma's end-to-end supply capability and peptide production experience are essential for growing commercial demand. Viking Therapeutics, Inc. (NASDAQ:VKTX) anticipates that the product will have conventional pharmaceutical margins and have a multibillion-dollar potential. It is among the Best Weight Loss Stocks. While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
